Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges
The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.
Abstract
Ovarian borderline (low malignant potential) tumors are a puzzling group of neoplasms that do not fall neatly into benign or malignant categories. Their behavior is enigmatic, their pathogenesis unclear, and their clinical management controversial, especially for serous borderline tumors (SBT), the most common type of ovarian borderline tumor. Clarifying the nature of borderline tumors and their relationship to invasive carcinoma has puzzled investigators since the category was created over 30 years ago. Much of the confusion and controversy concerning these tumors is due to a lack of understanding of their pathogenesis and an absence of a model for the development of ovarian carcinoma. This review summarizes recent molecular studies of ovarian borderline tumors with special emphasis on the role of SBT in tumor progression and its relationship to ovarian serous carcinoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“According to this hypothesis, hallmarks of the type II pathway are high grade, high proliferation index, and p53 mutations (Shih and Kurman, 2005; Singer et al, 2005).”
From Prognostic role of CIP2A expression in serous ovarian cancer (2011) · cites this paper as Shih and Kurman, 2005
In the citing paper
“Ovarian cancer has been proposed to evolve through two distinct molecular pathways: type I low-grade pathway tumours have a 5-year survival of 55% and have frequently activating mutations of BRAF or KRAS, whereas type II high-grade pathway tumours with a 5-year survival of only 30% are characterised by inactivating mutations of p53.”
From Prognostic role of CIP2A expression in serous ovarian cancer (2011) · cites this paper as Shih and Kurman, 2005
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Genetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Blaustein's Pathology of the Female Genital Tract
(2019) · Springer eBooks · doi:10.1007/978-3-319-46334-6 · Cited by 1,335
Self-citationRAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224
Research works printed but not linked: 2
- Scully RE. World Health Organization international histological classification of tumours. 2nd ed. New York (NY): Springer; 1999.
- Ichikawa Y, Nishida M, Suzuki H. Mutation of KRAS protooncogene is associated iwth histological subtypes in human mucinous ovarian tumors. Cancer Res 1994;54:33–5.
Cited by
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., deFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 787
Cho, K. R., & Shih, I.-M. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092246 · Cited by 694
“two broad categories, designated Type I and Type II tumors, based on their pattern of tumor progression and molecular genetic changes (137, 138).”
BackgroundSelf-citationKurman, R. J., & Shih, I.-M. (2008) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e318161e4f5 · Cited by 460
“The model divides surface epithelial tumors into 2 groups designated type I and type II (1,5).”
BackgroundSelf-citationNew Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact
Levanon, K., Crum, C., & Drapkin, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1107 · Cited by 412
Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary
Gershenson, D. M., Sun, C. C., Lu, K. H., Coleman, R. L., Sood, A. K., Malpica, A., Deavers, M. T., Silva, E. G., & Bodurka, D. C. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000227787.24587.d1 · Cited by 290
Metadata
- Authors
- Shih, I.-M., & Kurman, R. J.
- Affiliations
- Johns Hopkins University (US)
- ORCID
- Shih, Ie-Ming
- Venue
- Clinical Cancer Research
- Published
- 2005-10-15
- Volume
- 11
- Issue
- 20
- Pages
- 7273-7279
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2145474139
- Cited by
- 142
- References
- 80
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 6 · 2022: 3 · 2021: 4 · 2020: 1 · 2019: 4 · 2017: 3 · 2016: 9 · 2015: 4 · 2014: 3 · 2013: 12 · 2012: 6
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA103937)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- borderline ovarian tumors, low malignant potential, serous borderline tumor, serous ovarian cancer, tumor progression, molecular pathogenesis, invasive carcinoma
- MeSH terms
- Female, Humans, Models, Biological, Mutation, Ovarian Neoplasms, Gene Expression Regulation, Neoplastic, Cystadenoma, Serous, Disease Progression, Proto-Oncogene Proteins c-raf, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-0755
- The paper
- Shih, I.-M., & Kurman, R. J. (2005). Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-0755
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.